ArticleMicrosystems & nanoengineering2026
Cascading inertial microfluidics for high-throughput, multi-scale enrichment of tumor cells and intact clusters towards enhanced malignancy diagnosis.
Article in Microsystems & nanoengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The presence and abundance of malignant tumor cells (MTCs), particularly cell clusters (MTCCs) in clinical effusion samples serve as established correlative indicators for aggressive malignancy, elevated metastatic potential, and adverse clinical prognosis. While tumor cell-based liquid biopsy enables the detection of single MTCs, but clinical utility is limited by cellular damage and attrition of MTCCs. To overcome these limitations, we developed a cascaded inertial microfluidic device for high-throughput and multi-scale enrichment of both MTCs and intact MTCCs through two-stage inertial sorting. The parallelized serpentine microfluidics were employed as the first-stage sorter which depleted majority of background blood cell in an ultra-high throughput. The second-stage spiral microfluidics enabled further multi-scale enrichment of single MTCs and intact MTCCs from residual blood cells without cellular damage. After exploring the effects of particle size and flow rate on two-stage inertial sorting, cell enrichment performances using simulated samples were characterized. Quantitative results indicated a high recovery ratio of 81.7% and a high purity of 76.1% for enriched A549 cells, along with a high purity of 79.4% for A549 cell clusters. Using the cascaded microfluidic device, 50 mL pleural effusion samples were processed within 6.5 min, achieving a high purity of 68% for single MTCs and a high purity of 35% for intact MTCCs. Our cascaded inertial microfluidic device may provide a new tool for accelerating clinical cancer diagnosis and enhance malignancy assessment capability.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.